Physician profile
Oscar G Ramirez
NPI 1962497420
$8,219.26
in general payments reported to CMS, 2019-2025
37 companies · $18.48 in 2025
The $18.48 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $917 · 2020: $267 · 2021: $801 · 2022: $1,576 · 2023: $2,413 · 2024: $2,227 · 2025: $18.48.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,543 · Education: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,542.97 |
| Education | $115.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,501.00 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,013.98 | 2019-2024 | Entyvio, Gattex, Eohilia |
| Janssen Biotech, INC. | $928.10 | 2019-2025 | Stelara, Simponi, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $806.63 | 2019-2024 | Xifaxan, Trulance, Relistor |
| Pfizer INC. | $494.11 | 2019-2024 | |
| Celgene Corporation | $245.15 | 2022-2023 | Zeposia |
| Qol Medical, LLC | $241.67 | 2019-2024 | Sucraid, Sucraid |
| Gilead Sciences, INC. | $238.58 | 2021-2024 | |
| Braintree Laboratories, INC. | $187.51 | 2019-2024 | Sutab, Suflave |
| Ferring Pharmaceuticals INC. | $185.98 | 2019-2023 | Rebyota |
| Ardelyx, INC. | $124.53 | 2022-2024 | Ibsrela |
| Genzyme Corporation | $113.56 | 2023-2024 | |
| Redhill Biopharma INC. | $107.66 | 2021-2023 | Talicia |
| Lilly USA, LLC | $96.34 | 2024 | Omvoh |
| Regeneron Healthcare Solutions, INC. | $88.69 | 2022-2024 | Dupixent |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evoke Pharma, INC. | $78.38 | 2022-2024 | Gimoti |
| Nestle Healthcare Nutrition INC. | $75.79 | 2021-2023 | |
| Intercept Pharmaceuticals, INC. | $73.61 | 2021-2023 | Ocaliva |
| Phathom Pharmaceuticals, INC. | $69.32 | 2024 | Voquezna |
| Ironwood Pharmaceuticals, INC | $66.58 | 2020-2022 | |
| Daiichi Sankyo INC. | $60.60 | 2021 | |
| Cumberland Pharmaceuticals, INC. | $51.44 | 2019-2020 | |
| Aimmune Therapeutics, INC. | $51.00 | 2024 | |
| Shire North American Group INC | $48.77 | 2019 | |
| Merck Sharp & Dohme LLC | $40.77 | 2023-2024 | Dificid |
| Janssen Pharmaceuticals, INC | $35.28 | 2022 | |
| Madrigal Pharmaceuticals | $31.78 | 2024 | Resmetirom |
| Ipsen Biopharmaceuticals, INC | $30.74 | 2024 | Iqirvo |
| Fresenius Kabi USA, LLC | $23.03 | 2023 | Idacio |
| Romark Laboratories, Lc | $20.44 | 2020 | |
| Alcresta Therapeutics, INC. | $17.48 | 2023 | Relizorb |
| Allergan, INC. | $16.72 | 2019 | |
| Celltrion USA INC. | $16.45 | 2024 | Zymfentra |
| Olympus America INC. | $14.64 | 2021 | |
| Shionogi INC | $12.91 | 2019 | |
| Micro-Tech Endoscopy USA, INC. | $10.04 | 2019-2024 | Forceps |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$81,225.85 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Oscar Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.